Ko Kisung
Department of Medicine, Therapeutic Protein Engineering Lab, College of Medicine, Chung-Ang University , Seoul, Korea.
Monoclon Antib Immunodiagn Immunother. 2014 Jun;33(3):192-8. doi: 10.1089/mab.2014.0049.
Plants are able to perform post-translational maturations of therapeutic proteins required for their functional biological activity and suitable in vivo pharmacokinetics. Plants can be a low-cost, large-scale production platform of recombinant biopharmaceutical proteins such as vaccines and antibodies. Plants, however, lack mechanisms of processing authentic human N-glycosylation, which imposes a major limitation in their use as an expression system for therapeutic glycoproducts. Efforts have been made to circumvent plant-specific N-glycosylation, as well as to supplement the plant's endogenous system with human glycosyltransferases for non-immunogenic and humanized N-glycan production. Herein we review studies on the potential of plants to serve as production systems for therapeutic and prophylactic biopharmaceuticals. We have especially focused on recombinant vaccines and antibodies and new expression strategies to overcome the existing problems associated with their production in plants.
植物能够对治疗性蛋白质进行翻译后成熟，以实现其功能性生物活性和合适的体内药代动力学。植物可以成为重组生物制药蛋白（如疫苗和抗体）的低成本、大规模生产平台。然而，植物缺乏加工真实人类N-糖基化的机制，这在其作为治疗性糖产品表达系统的应用中构成了主要限制。人们已努力规避植物特异性N-糖基化，并用人糖基转移酶补充植物内源性系统以生产非免疫原性和人源化N-聚糖。在此，我们综述了关于植物作为治疗性和预防性生物制药生产系统潜力的研究。我们特别关注了重组疫苗和抗体以及克服与它们在植物中生产相关现有问题的新表达策略。
